Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


How COVID-19 disrupts glycometabolic control

Coronavirus disease 2019 (COVID-19) is associated with hyperglycaemia. A study published in Nature Metabolism now shows how hyperglycaemia develops in a cohort of 551 patients hospitalized with COVID-19 in Italy.

“We started from a clinical observation: in patients hospitalized for COVID-19, there is a huge rate of new-onset hyperglycaemia,” explains corresponding author Paolo Fiorina. “In these patients, clinical outcomes are the poorest, with more requirement for ventilation, need of ICU and longer length of hospitalization.” Of note, these patients did not have pre-existing diabetes mellitus, as their levels of HbA1c were normal.

Credit: STANCA SANDA/ Alamy Stock Photo

In patients with new-onset hyperglycaemia at hospital admission for COVID-19, persistent hyperglycaemia (6 months) was observed in 35%, diabetes mellitus was diagnosed in 2% and the remaining patients became normoglycaemic. Continuous glucose monitoring was used in a small number of patients with COVID-19 to confirm the impaired glycaemic profile. Importantly, this approach showed some glycaemic alterations also persisted in some of those who had recovered from COVID-19.

The serum hormone profile (tested under fasting conditions and arginine stimulation) was altered in patients with COVID-19 and patients who had recovered from COVID-19. These changes demonstrated persistent insulin resistance and suggested that β-cell hyperstimulation might be occurring in COVID-19.

“Patients with COVID-19 also showed changes in the cytokine secretome”

Patients with COVID-19 also showed changes in the cytokine secretome, which persisted long after recovery. Of note, using tocilizumab (anti-IL-6) to treat patients with COVID-19, new-onset hyperglycaemia and high levels of IL-6 reduced glycaemia. This preliminary finding suggests a mechanistic link between disrupted cytokines and glycaemia in COVID-19. “Our data demonstrate that COVID-19 is associated with aberrant glycometabolic control, which can persist even after recovery,” concludes Fiorina. “These data suggest that further investigation of metabolic abnormalities in the context of long COVID is warranted.”


Original article

  1. Montefusco, L. et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat. Metab. (2021)

    Article  PubMed  Google Scholar 

Related article

  1. Lim, S. et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat. Rev. Endocrinol. 17, 11–30 (2021)

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Shimona Starling.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Starling, S. How COVID-19 disrupts glycometabolic control. Nat Rev Endocrinol 17, 448 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing